144 related articles for article (PubMed ID: 23600722)
1. AT1 blockade abolishes left ventricular hypertrophy in heterozygous cMyBP-C null mice: role of FHL1.
Vignier N; Le Corvoisier P; Blard C; Sambin L; Azibani F; Schlossarek S; Delcayre C; Carrier L; Hittinger L; Su JB
Fundam Clin Pharmacol; 2014 Jun; 28(3):249-56. PubMed ID: 23600722
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II subtype-1 receptor blockade during the development of left ventricular hypertrophy in dogs: effects on ventricular and myocyte function.
Spinale FG; Holzgrefe HH; Walker JD; Mukherjee R; Kribbs SB; Powell JR; Antonaccio M
J Cardiovasc Pharmacol; 1997 Nov; 30(5):623-31. PubMed ID: 9388045
[TBL] [Abstract][Full Text] [Related]
3. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.
Stöhr A; Friedrich FW; Flenner F; Geertz B; Eder A; Schaaf S; Hirt MN; Uebeler J; Schlossarek S; Carrier L; Hansen A; Eschenhagen T
J Mol Cell Cardiol; 2013 Oct; 63():189-98. PubMed ID: 23896226
[TBL] [Abstract][Full Text] [Related]
4. Altered myocardial gene expression reveals possible maladaptive processes in heterozygous and homozygous cardiac myosin-binding protein C knockout mice.
Eijssen LM; van den Bosch BJ; Vignier N; Lindsey PJ; van den Burg CM; Carrier L; Doevendans PA; van der Vusse GJ; Smeets HJ
Genomics; 2008 Jan; 91(1):52-60. PubMed ID: 18060737
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin AT1 receptor inhibition. Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis.
Weinberg EO; Lee MA; Weigner M; Lindpaintner K; Bishop SP; Benedict CR; Ho KK; Douglas PS; Chafizadeh E; Lorell BH
Circulation; 1997 Mar; 95(6):1592-600. PubMed ID: 9118530
[TBL] [Abstract][Full Text] [Related]
6. Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction.
Fraccarollo D; Galuppo P; Schmidt I; Ertl G; Bauersachs J
Cardiovasc Res; 2005 Jul; 67(1):97-105. PubMed ID: 15949473
[TBL] [Abstract][Full Text] [Related]
7. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
[TBL] [Abstract][Full Text] [Related]
8. Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice.
Schlossarek S; Schuermann F; Geertz B; Mearini G; Eschenhagen T; Carrier L
J Muscle Res Cell Motil; 2012 May; 33(1):5-15. PubMed ID: 22076249
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman P; Nyström F; Hägg A; Lind L
J Hypertens; 2002 Apr; 20(4):657-63. PubMed ID: 11910301
[TBL] [Abstract][Full Text] [Related]
10. B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Hallberg P; Lind L; Michaëlsson K; Karlsson J; Kurland L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Melhus H
J Hypertens; 2003 Mar; 21(3):621-4. PubMed ID: 12640257
[TBL] [Abstract][Full Text] [Related]
11. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial.
Kurland L; Hallberg P; Melhus H; Liljedahl U; Hashemi N; Syvänen AC; Lind L; Kahan T
Am J Hypertens; 2008 Jul; 21(7):836-9. PubMed ID: 18464745
[TBL] [Abstract][Full Text] [Related]
12. Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice.
Carrier L; Knöll R; Vignier N; Keller DI; Bausero P; Prudhon B; Isnard R; Ambroisine ML; Fiszman M; Ross J; Schwartz K; Chien KR
Cardiovasc Res; 2004 Aug; 63(2):293-304. PubMed ID: 15249187
[TBL] [Abstract][Full Text] [Related]
13. Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study.
Grandi AM; Solbiati F; Laurita E; Maresca AM; Nicolini E; Marchesi C; Gianni M; Guasti L; Venco A
Am J Hypertens; 2008 Feb; 21(2):231-7. PubMed ID: 18174880
[TBL] [Abstract][Full Text] [Related]
14. Endothelial Protection, AT1 blockade and Cholesterol-Dependent Oxidative Stress: the EPAS trial.
Morawietz H; Erbs S; Holtz J; Schubert A; Krekler M; Goettsch W; Kuss O; Adams V; Lenk K; Mohr FW; Schuler G; Hambrecht R
Circulation; 2006 Jul; 114(1 Suppl):I296-301. PubMed ID: 16820589
[TBL] [Abstract][Full Text] [Related]
15. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
Mörtsell D; Malmqvist K; Held C; Kahan T
J Intern Med; 2007 May; 261(5):472-9. PubMed ID: 17444886
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Hallberg P; Lind L; Billberger K; Michaelsson K; Karlsson J; Kurland L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Liljedahl U; Syvänen AC; Melhus H
Clin Cardiol; 2004 Mar; 27(3):169-73. PubMed ID: 15049387
[TBL] [Abstract][Full Text] [Related]
17. Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice.
Barefield D; Kumar M; Gorham J; Seidman JG; Seidman CE; de Tombe PP; Sadayappan S
J Mol Cell Cardiol; 2015 Feb; 79():234-43. PubMed ID: 25463273
[TBL] [Abstract][Full Text] [Related]
18. AT1 receptor blockade prevents cardiac dysfunction after myocardial infarction in rats.
Berthonneche C; Sulpice T; Tanguy S; O'Connor S; Herbert JM; Janiak P; de Leiris J; Boucher F
Cardiovasc Drugs Ther; 2005 Aug; 19(4):251-9. PubMed ID: 16193242
[TBL] [Abstract][Full Text] [Related]
19. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study.
Penicka M; Gregor P; Kerekes R; Marek D; Curila K; Krupicka J;
J Mol Diagn; 2009 Jan; 11(1):35-41. PubMed ID: 19074594
[TBL] [Abstract][Full Text] [Related]
20. The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction.
Tschöpe C; Spillmann F; Altmann C; Koch M; Westermann D; Dhayat N; Dhayat S; Bascands JL; Gera L; Hoffmann S; Schultheiss HP; Walther T
Cardiovasc Res; 2004 Feb; 61(3):559-69. PubMed ID: 14962486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
